Novartis' oral multiple sclerosis drug remibrutinib meaningfully reduced relapses in patients but showed less efficacy than expected in phase 3 trials, potentially giving competitor Roche an advantage with its rival treatment.
Britain's Competition and Markets Authority proposed designating Microsoft with 'strategic market status' in business software, potentially enabling interventions in how the company bundles products and makes it harder for customers to switch providers.